Generic Name and Formulations:
Liothyronine (as sodium) 10mcg/mL; soln for IV inj.
Par Pharmaceutical, Inc.
Indications for TRIOSTAT:
Give with glucocorticoids. Allow 4–12 hours between doses. Initially 25–50mcg. Cardiovascular disease: initially 10–20mcg. Usual range: 65–100mcg daily. Change to oral therapy as soon as possible: start tabs at low dose and increase gradually; discontinue IV gradually.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis. Artificial rewarming.
Not for treatment of obesity for weight loss.
Ineffective for weight reduction in euthyroid patients. Not for treatment of infertility. Cardiovascular disease, angina, elderly: initiate therapy at 10–20micrograms. Severe and prolonged hypothyroidism. Fluid therapy. Adrenocortical insufficiency. Pregnancy (Cat.A). Nursing mothers.
Potentiates digitalis toxicity, tricyclic antidepressants, sympathomimetics (eg, anorectics). May increase risk of coronary insufficiency with vasopressors. Monitor oral anticoagulants, hypoglycemics. Estrogens affect thyroid function tests. May be potentiated by tricyclic antidepressants. Hypertension, tachycardia with ketamine.
Arrhythmia, tachycardia, cardiopulmonary arrest, hypotension, MI, angina, CHF, hypertension, twitching.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness